MARKET

PRME

PRME

Prime Medicine
NASDAQ
3.737
-0.113
-2.95%
Opening 13:14 12/05 EST
OPEN
3.880
PREV CLOSE
3.850
HIGH
3.940
LOW
3.705
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
6.94
52 WEEK LOW
1.110
MARKET CAP
674.50M
P/E (TTM)
-2.5920
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PRME last week (1124-1128)?
Weekly Report · 4d ago
Prime Medicine CEO to Join Fireside Chat at Evercore Healthcare Conference
Reuters · 11/25 13:00
Weekly Report: what happened at PRME last week (1117-1121)?
Weekly Report · 11/24 09:40
Citizens JMP healthcare analysts hold an analyst/industry conference
TipRanks · 11/18 17:15
Prime Medicine transferred with Neutral rating at JPMorgan
TipRanks · 11/18 12:55
Weekly Report: what happened at PRME last week (1110-1114)?
Weekly Report · 11/17 09:41
Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline
TipRanks · 11/13 11:37
Prime Medicine’s Promising Advances in Gene Editing Justify Buy Rating
TipRanks · 11/11 21:16
More
About PRME
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Webull offers Prime Medicine Inc stock information, including NASDAQ: PRME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRME stock methods without spending real money on the virtual paper trading platform.